Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study Conference Paper uri icon

authors

  • Sandhu, S
  • Hill, A
  • Gan, H
  • Friedlander, M
  • Voskoboynik, M
  • Barlow, P
  • Townsend, A
  • Song, J
  • Zhang, Y
  • Liang, L
  • Desai, J

publication date

  • December 1, 2018